EUVIMEDEUVIMED entdecken
Crossref

Establishment of a high-throughput scale-down clone screening platform for intensified fed-batch culture of CHO cells

Haiyan Luo, Shuai Wang, Collin Chong, Lile Wang, Xiaojun Sun, Qian Guo, Sam Zhang, Xiaoyue Chen, Hang Zhou, Weichang Zhou

Biotechnology Letters · 2025

DOI: 10.1007/s10529-025-03573-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Letters, 2025. Verfasst von Haiyan Luo und 9 weiteren Autor:innen. Beteiligte Einrichtung: WuXi Biologics, Cell Line Development, Mashan, Wuxi, China. Hauptthemen laut MEDLINE: Batch Cell Culture Techniques, Antibodies, Monoclonal, High-Throughput Screening Assays. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To develop a scale-down clone screening platform for the intensified fed-batch (IFB) process to allow efficient identification of high expressing clones fitting the IFB culture strategy in bioreactor. RESULTS: Three monoclonal antibodies (mAbs) were used in the development and validation of the IFB specific clone screening platform for CHO cells. The IFB platform significantly improved titer levels, achieving an average titer of 8 g/L and the highest titer of 9.6 g/L. With similar cell viability, lactate profile and titer levels, both the spin tube model and the AMBR250@ bioreactor system were effective in screening clones suitable for IFB process. The addition of aurintricarboxylic acid (ATA) and uridine in the process optimization led to a further increase in expression levels in both systems, achieving the highest titer of 12.2 g/L. CONCLUSION: This IFB-process specific clone screening serves as an alternative platform for industry application that can increase the effectiveness and efficiency of screening high-expressing CHO cell lines for IFB production.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Batch Cell Culture TechniquesAntibodies, MonoclonalHigh-Throughput Screening AssaysCHO CellsAnimalsCricetulusBioreactorsCell Survival

Stichwörter der Autor:innen

CHO cell cultureClone screeningIntensified fed-batchMammalian cell line development

Substanzen

Antibodies, Monoclonal

Autor:innen und Institutionen

  • WuXi Biologics, Cell Line Development, Mashan, Wuxi, China.
  • WuXi Biologics, Protein Science, Mashan, Wuxi, China.
  • WuXi Biologics, Microbial and Viral Platforms, Economic & Technological Development Zone, Hangzhou, China.
  • WuXi Biologics, Cell Line Development, Waigaoqiao Free Trade Zone, Shanghai, China. chen_xiaoyue@wuxibiologics.com.
  • WuXi Biologics, Bioprocess Research and Development, Waigaoqiao Free Trade Zone, Shanghai, China.
  • WuXi Biologics, Honorary President of WuXi Biologics and Senior Advisor to CEO, Waigaoqiao Free Trade Zone, Shanghai, China.

Zitieren

APA

Luo, H., Wang, S., Chong, C., Wang, L., Sun, X., Guo, Q., Zhang, S., Chen, X., Zhou, H., & Zhou, W. (2025). Establishment of a high-throughput scale-down clone screening platform for intensified fed-batch culture of CHO cells. Biotechnology Letters. https://doi.org/10.1007/s10529-025-03573-9

Vancouver

Luo H, Wang S, Chong C, Wang L, Sun X, Guo Q, et al. Establishment of a high-throughput scale-down clone screening platform for intensified fed-batch culture of CHO cells. Biotechnology Letters. 2025. doi:10.1007/s10529-025-03573-9

BibTeX
@article{Luo2025,
  author = {Luo, Haiyan and Wang, Shuai and Chong, Collin and Wang, Lile and Sun, Xiaojun and Guo, Qian and Zhang, Sam and Chen, Xiaoyue and Zhou, Hang and Zhou, Weichang},
  title = {Establishment of a high-throughput scale-down clone screening platform for intensified fed-batch culture of CHO cells},
  journal = {Biotechnology Letters},
  year = {2025},
  doi = {10.1007/s10529-025-03573-9}
}
Kostenlos starten →